Galapagos Acquires CellPoint and AboundBio for Over $250 Million
Galapagos has inked purchase deals with two biotech companies, CellPoint and AboundBio, aimed at developing chimeric antigen receptor (CAR)-T therapies.
The acquisition deal with CellPoint includes an upfront payment of over $131 million and potential milestone payments of up to $105 million. The AboundBio purchase is priced at $14 million.
CellPoint has developed a 6-day manufacturing process that allows for a one-week vein-to-vein time compared to over one month with current CAR-T manufacturing methods. A first proprietary CD19 CAR-T investigational therapy is currently in phase 1/2a trials to assess the decentralized point-of-care production model.
With the acquisition of AboundBio, Galapagos will gain access to the company’s antibody technology to help develop next-generation CAR-Ts and bispecific antibodies.
Galapagos NV
Galapagos NV (formerly known as Galapagos Genomics) is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins. In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration.
June 24, 2022
https://www.fdanews.com/
